drugset / Trial / NCT00140088

Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.

NCT00140088 ↗

Phase 3 Completed 504 enrolled AlgoRx Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Minor needlestick procedures often cause significant pain and distress in pediatric patients yet interventions to reduce pain are used infrequently. ALGRX 3268 is a novel, single-use, prefilled, needle-free product that immediately delivers powdered lidocaine into the epidermis and provides local analgesia in 2-3 minutes. The purpose of this phase III, prospective, randomized, double-blind, placebo-controlled study is to investigate the efficacy, safety and tolerability of ALGRX 3268 versus placebo in pediatric patients aged 3 to 18 years undergoing venipuncture or peripheral venous canulation procedures. The trial will enroll approximate 504 evaluable subjects at centers located in the US.

Timeline

Start
2004-12
Primary completion
—
Completion
2005-04

Outcome

Met primary endpoint

paper The active system group had significantly (P = 0.0022) less pain compared with the sham placebo PMID 26164784 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 0.5 mg Topical

Indications

No indication recorded.